Logo image of INM

INMED PHARMACEUTICALS INC (INM) Stock Fundamental Analysis

NASDAQ:INM - Nasdaq - CA4576377002 - Common Stock

5.05  +0.1 (+2.02%)

Premarket: 4.41 -0.64 (-12.67%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INM. INM was compared to 195 industry peers in the Pharmaceuticals industry. INM has a great financial health rating, but its profitability evaluates not so good. INM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

INM had negative earnings in the past year.
In the past year INM has reported a negative cash flow from operations.
INM had negative earnings in each of the past 5 years.
INM had a negative operating cash flow in each of the past 5 years.
INM Yearly Net Income VS EBIT VS OCF VS FCFINM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -65.14%, INM is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
INM has a Return On Equity of -81.19%. This is comparable to the rest of the industry: INM outperforms 45.70% of its industry peers.
Industry RankSector Rank
ROA -65.14%
ROE -81.19%
ROIC N/A
ROA(3y)-88.9%
ROA(5y)-97.12%
ROE(3y)-117.99%
ROE(5y)-128.85%
ROIC(3y)N/A
ROIC(5y)N/A
INM Yearly ROA, ROE, ROICINM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

INM's Gross Margin of 31.71% is in line compared to the rest of the industry. INM outperforms 55.91% of its industry peers.
INM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INM Yearly Profit, Operating, Gross MarginsINM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

INM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INM has been reduced compared to 1 year ago.
Compared to 5 years ago, INM has more shares outstanding
There is no outstanding debt for INM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INM Yearly Shares OutstandingINM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
INM Yearly Total Debt VS Total AssetsINM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

INM has an Altman-Z score of -14.91. This is a bad value and indicates that INM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INM (-14.91) is worse than 81.72% of its industry peers.
INM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.91
ROIC/WACCN/A
WACC9.25%
INM Yearly LT Debt VS Equity VS FCFINM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 5.07 indicates that INM has no problem at all paying its short term obligations.
INM's Current ratio of 5.07 is fine compared to the rest of the industry. INM outperforms 65.59% of its industry peers.
INM has a Quick Ratio of 4.22. This indicates that INM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INM (4.22) is better than 62.37% of its industry peers.
Industry RankSector Rank
Current Ratio 5.07
Quick Ratio 4.22
INM Yearly Current Assets VS Current LiabilitesINM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

INM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2661.35%.
The Revenue has been growing slightly by 5.32% in the past year.
EPS 1Y (TTM)-2661.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7020.3%
Revenue 1Y (TTM)5.32%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INM Yearly Revenue VS EstimatesINM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
INM Yearly EPS VS EstimatesINM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INM Price Earnings VS Forward Price EarningsINM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INM Per share dataINM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMED PHARMACEUTICALS INC

NASDAQ:INM (1/21/2025, 8:07:43 PM)

Premarket: 4.41 -0.64 (-12.67%)

5.05

+0.1 (+2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-11 2025-02-11
Inst Owners5.55%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change-0.06%
Market Cap3.64M
Analysts45
Price TargetN/A
Short Float %1.31%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.73
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-65.44
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-9.24
FCFYN/A
OCF(TTM)-9.23
OCFYN/A
SpS6.89
BVpS11.66
TBVpS9.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.14%
ROE -81.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.71%
FCFM N/A
ROA(3y)-88.9%
ROA(5y)-97.12%
ROE(3y)-117.99%
ROE(5y)-128.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.07
Quick Ratio 4.22
Altman-Z -14.91
F-Score3
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)35.09%
Cap/Depr(5y)28.33%
Cap/Sales(3y)2.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2661.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7020.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.32%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.27%
OCF growth 3YN/A
OCF growth 5YN/A